- Home
- NVVE vs VIVS Comparison
NVVE vs VIVS Comparison
Compare NVVE & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVVE
- VIVS
- Stock Information
- Founded
- NVVE 1996
- VIVS 2007
- Country
- NVVE United States
- VIVS United States
- Employees
- NVVE N/A
- VIVS N/A
- Industry
- NVVE Oil Refining/Marketing
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NVVE Energy
- VIVS Health Care
- Exchange
- NVVE Nasdaq
- VIVS Nasdaq
- Market Cap
- NVVE 4.2M
- VIVS 4.7M
- IPO Year
- NVVE N/A
- VIVS N/A
- Fundamental
- Price
- NVVE $0.27
- VIVS $3.19
- Analyst Decision
- NVVE
- VIVS
- Analyst Count
- NVVE 0
- VIVS 0
- Target Price
- NVVE N/A
- VIVS N/A
- AVG Volume (30 Days)
- NVVE 1.5M
- VIVS 166.7K
- Earning Date
- NVVE 11-11-2025
- VIVS 11-07-2025
- Dividend Yield
- NVVE N/A
- VIVS N/A
- EPS Growth
- NVVE N/A
- VIVS N/A
- EPS
- NVVE N/A
- VIVS N/A
- Revenue
- NVVE $4,949,747.00
- VIVS $142,000.00
- Revenue This Year
- NVVE $892.33
- VIVS $42.38
- Revenue Next Year
- NVVE N/A
- VIVS $15.42
- P/E Ratio
- NVVE N/A
- VIVS N/A
- Revenue Growth
- NVVE N/A
- VIVS 94.52
- 52 Week Low
- NVVE $0.18
- VIVS $1.41
- 52 Week High
- NVVE $5.02
- VIVS $21.96
- Technical
- Relative Strength Index (RSI)
- NVVE 37.29
- VIVS 51.15
- Support Level
- NVVE $0.22
- VIVS $2.90
- Resistance Level
- NVVE $0.30
- VIVS $3.48
- Average True Range (ATR)
- NVVE 0.02
- VIVS 0.34
- MACD
- NVVE 0.02
- VIVS -0.09
- Stochastic Oscillator
- NVVE 57.77
- VIVS 20.86
About NVVE Nuvve Holding Corp.
Nuvve Holding Corp is accelerating the electrification of transportation through its proprietary vehicle-to-grid (V2G) technology. It helps to support the integration of renewable energy sources, including solar and wind. Its Grid Integrated Vehicle (GIV) platform is refueling the next generation of electric vehicle fleets through bidirectional charging solutions. It has a geographic presence in the United States, the United Kingdom, and Denmark, of which it generates the majority of its revenue in the United States.
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.